Electromed, Inc.

Electromed develops, manufactures, and markets airway clearance therapy systems based on high frequency chest wall oscillation (HFCWO) technology for patients with compromised pulmonary function. The company's primary product platform, SmartVest, is designed for patients with conditions including cystic fibrosis, bronchiectasis, and neuromuscular disorders such as cerebral palsy, muscular dystrophies, and amyotrophic lateral sclerosis. The SmartVest system consists of an inflatable therapy garment, a programmable air pulse generator, and delivery mechanisms that create oscillatory pressure on the chest wall to facilitate airway clearance.

The company offers multiple product variants to serve different care settings and patient needs. SmartVest Connect incorporates wireless technology enabling remote data connectivity between physicians and patients for treatment monitoring and collaborative care decisions. Additional offerings include single-patient-use SmartVest products and SmartVest Wrap systems designed for acute care environments. The company markets its products through multiple channels, including direct sales to physicians and healthcare providers as well as direct-to-patient sales.

Electromed operates at a modest scale with 177 full-time employees and is headquartered in New Prague, Minnesota. The company serves both the U.S. and international markets, though the majority of revenue is generated domestically. Distribution extends across various healthcare settings, from specialty clinics to hospitals and home care environments.